



## Ongoing Disclosure Notice

### Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

|                            |
|----------------------------|
| To NZX Limited; and        |
| Name of listed issuer:     |
| Date this disclosure made: |
| Date of last disclosure:   |

|                                                |
|------------------------------------------------|
| Fisher & Paykel Healthcare Corporation Limited |
| 15-Dec-17                                      |
| 05-Oct-17                                      |

#### Director or senior manager giving disclosure

|                                                 |
|-------------------------------------------------|
| Full name(s):                                   |
| Name of listed issuer:                          |
| Name of related body corporate (if applicable): |
| Position held in listed issuer:                 |

|                                                |
|------------------------------------------------|
| Lewis George Gradon                            |
| Fisher & Paykel Healthcare Corporation Limited |
|                                                |
| Chief Executive Officer                        |

#### Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

|                                                      |
|------------------------------------------------------|
| Class of affected quoted financial products:         |
| Nature of the affected relevant interest(s):         |
| <b>For that relevant interest:</b>                   |
| Number held in class before acquisition or disposal: |
| Number held in class after acquisition or disposal:  |
| Current registered holder(s):                        |
| Registered holder(s) once transfers are registered:  |

|                                                |
|------------------------------------------------|
| (a) Ordinary Shares                            |
| (b) Options to acquire Ordinary Shares         |
| Beneficial Interest in Ordinary Shares         |
|                                                |
| (a) 298,462 Ordinary Shares                    |
| (b) 398,364 Options to acquire Ordinary Shares |
| (a) 327,089 Ordinary Shares                    |
| (b) 336,364 Options to acquire Ordinary Shares |
| Lewis George Gradon                            |
| Lewis George Gradon                            |

#### Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

|                                         |
|-----------------------------------------|
| Type of affected derivative:            |
| Class of underlying financial products: |

|                |
|----------------|
| Not Applicable |
|----------------|

#### Details of affected derivative:

|                                                                                                                                                                                                       |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):                                                                                       |
| A statement as to whether the derivative is cash settled or physically settled:                                                                                                                       |
| Maturity date of the derivative (if any):                                                                                                                                                             |
| Expiry date of the derivative(if any):                                                                                                                                                                |
| The price specified in the terms of the derivative (if any):                                                                                                                                          |
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: |

|  |
|--|
|  |
|  |
|  |
|  |
|  |
|  |

#### For that derivative:

|                                                                                                                            |
|----------------------------------------------------------------------------------------------------------------------------|
| Parties to the derivative:                                                                                                 |
| If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: |

|  |
|--|
|  |
|  |

#### Details of transactions giving rise to acquisition or disposal

|                                                       |
|-------------------------------------------------------|
| Total number of transactions to which notice relates: |
|-------------------------------------------------------|

|     |
|-----|
| Two |
|-----|

#### Details of transactions requiring disclosure:

|                      |
|----------------------|
| Date of transaction: |
|----------------------|

|                      |
|----------------------|
| (a) 13 December 2017 |
| (b) 13 December 2017 |

